Dianexin - Kowa

Drug Profile

Dianexin - Kowa

Alternative Names: Annexin A5 - Kowa; Annexin V - Kowa; Calphobindin; Caphobindin 1; Carfovindin; CPB I; KK 001; rCPB I

Latest Information Update: 17 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Akita University; Kowa
  • Class Anti-inflammatories; Anti-ischaemics; Anticoagulants; Antithrombotics; Biological peptides; Calcium binding proteins; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Phosphatidylserine receptor modulators; Phospholipase A2 inhibitors; Urokinase-type plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Blood coagulation disorders

Most Recent Events

  • 18 Feb 2005 Discontinued - Preclinical for Coagulation disorders in Japan (unspecified route)
  • 14 Jan 2004 No development reported - Preclinical for Coagulation disorders in Japan (unspecified route)
  • 19 Mar 2002 Calphobindin 1 is now called annexin V
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top